IDH2 and glioblastoma: Diffuse astrocytic glioma IDH wild-type (IDHwt) presenting with disadvantageous genetic characteristics (e.g., epidermal growth factor receptor gene (EGFR) amplification or combined chromosome 7 gain/chromosome 10 loss or telomerase reverse transcriptase (TERT) promoter mutation) was proposed to be a “diffuse astrocytic glioma, IDHwt, with molecular features of glioblastoma” [14] and will be termed glioblastoma in the upcoming revised 2021 classification.